HR 340

The HCT/P Modernization Act of 2025

Congress: 119 (2025–2027, Current)
Chamber: House
Policy Area: Health
Introduced: Jan 13, 2025
Current Status: Referred to the House Committee on Energy and Commerce.
Latest Action: Referred to the House Committee on Energy and Commerce. (Jan 13, 2025)
Official Text: https://www.congress.gov/bill/119th-congress/house-bill/340

Sponsor

Name: Rep. Crenshaw, Dan [R-TX-2]
Party: Republican • **State:** TX • **Chamber:** House

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Barragán, Nanette Diaz [D-CA-44]	D · CA		Jan 13, 2025

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	Jan 13, 2025

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
119 HR 1082	Related bill	**Jun 24, 2025:** Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summary (as of Jan 13, 2025)

The HCT/P Modernization Act of 2025

This bill requires the Food and Drug Administration (FDA) to provide information to stakeholders and report on the regulation of human cell and tissue products, also referred to as human cells, tissues, or cellular or tissue-based products (HCT/Ps), which are articles containing or consisting of human cells or tissues that are intended for use in a human recipient.

The bill requires the FDA to conduct workshops to educate stakeholders and facilitate discussion with them on advancing the science and regulation of human cell and tissue products. The FDA must establish a public docket to receive written comments on this topic, and submit to Congress a report with recommendations on regulating these products.

Additionally, the bill requires the FDA to publish on its website educational materials about the Tissue Reference Group and best practices for obtaining a recommendation about products from them. Also, annually for three years, the FDA must publish on its website information on the inquiries submitted and average response times for the Tissue Reference Group, as well as the number of human cell and tissue manufacturers that have registered with the FDA and the number of inspections the FDA has conducted with respect to these manufacturers since 2019. (The Tissue Reference Group is a working group within the FDA that receives product-specific questions from, and provides recommendations for, stakeholders on the regulation of human cell and tissue products under the FDA’s rules.)

Actions Timeline

- **Jan 13, 2025:** Introduced in House
- **Jan 13, 2025:** Introduced in House
- **Jan 13, 2025:** Referred to the House Committee on Energy and Commerce.
- **Jan 13, 2025:** Introduced in House
- **Jan 13, 2025:** Introduced in House
- **Jan 13, 2025:** Referred to the House Committee on Energy and Commerce.
- **Jan 13, 2025:** Introduced in House
- **Jan 13, 2025:** Introduced in House
- **Jan 13, 2025:** Referred to the House Committee on Energy and Commerce.
- **Jan 13, 2025:** Introduced in House
- **Jan 13, 2025:** Introduced in House
- **Jan 13, 2025:** Referred to the House Committee on Energy and Commerce.
- **Jan 13, 2025:** Introduced in House
- **Jan 13, 2025:** Introduced in House
- **Jan 13, 2025:** Referred to the House Committee on Energy and Commerce.
- **Jan 13, 2025:** Introduced in House
- **Jan 13, 2025:** Referred to the House Committee on Energy and Commerce.